Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Status:
Completed
Trial end date:
2021-07-13
Target enrollment:
Participant gender:
Summary
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and
best schedule of the combination of everolimus and sorafenib that can be given to patients
with malignant glioma.
The goal of Phase 2 of this study to learn if the combination of everolimus and sorafenib can
help to control malignant glioma. The safety of this combination will also be studied in both
phases.